Ｖｅｒｉｔａｓ Ｉｎ Ｓｉｌｉｃｏの株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2024/05/16 | 1,130 | 1,160 | 1,090 | 1,110 | -20 | -1.8% | 58,000 |
| 2024/05/15 | 1,200 | 1,220 | 1,123 | 1,130 | -64 | -5.4% | 88,900 |
| 2024/05/14 | 1,186 | 1,238 | 1,186 | 1,194 | +9 | +0.8% | 52,600 |
| 2024/05/13 | 1,185 | 1,213 | 1,139 | 1,185 | ±0 | ±0% | 124,500 |
| 2024/05/10 | 1,381 | 1,383 | 1,178 | 1,185 | -218 | -15.5% | 192,400 |
| 2024/05/09 | 1,465 | 1,470 | 1,401 | 1,403 | -92 | -6.2% | 86,900 |
| 2024/05/08 | 1,580 | 1,581 | 1,470 | 1,495 | -135 | -8.3% | 197,400 |
| 2024/05/07 | 1,910 | 1,929 | 1,578 | 1,630 | -240 | -12.8% | 167,100 |
| 2024/05/02 | 1,817 | 1,897 | 1,800 | 1,870 | +55 | +3% | 59,600 |
| 2024/05/01 | 1,691 | 1,840 | 1,691 | 1,815 | +84 | +4.9% | 60,100 |
| 2024/04/30 | 1,670 | 1,813 | 1,600 | 1,731 | +54 | +3.2% | 59,300 |
| 2024/04/26 | 1,635 | 1,700 | 1,595 | 1,677 | +42 | +2.6% | 24,400 |
| 2024/04/25 | 1,650 | 1,650 | 1,581 | 1,635 | -17 | -1% | 16,200 |
| 2024/04/24 | 1,677 | 1,692 | 1,652 | 1,652 | -41 | -2.4% | 13,600 |
| 2024/04/23 | 1,670 | 1,716 | 1,635 | 1,693 | +23 | +1.4% | 12,500 |
| 2024/04/22 | 1,625 | 1,670 | 1,585 | 1,670 | +50 | +3.1% | 15,300 |
| 2024/04/19 | 1,652 | 1,666 | 1,600 | 1,620 | -49 | -2.9% | 35,800 |
| 2024/04/18 | 1,650 | 1,686 | 1,620 | 1,669 | +19 | +1.2% | 18,200 |
| 2024/04/17 | 1,701 | 1,730 | 1,650 | 1,650 | -59 | -3.5% | 36,100 |
| 2024/04/16 | 1,746 | 1,789 | 1,688 | 1,709 | -37 | -2.1% | 30,500 |
| 2024/04/15 | 1,660 | 1,750 | 1,657 | 1,746 | +46 | +2.7% | 28,700 |
| 2024/04/12 | 1,791 | 1,825 | 1,700 | 1,700 | -91 | -5.1% | 30,800 |
| 2024/04/11 | 1,847 | 1,847 | 1,770 | 1,791 | -29 | -1.6% | 23,700 |
| 2024/04/10 | 1,750 | 1,820 | 1,690 | 1,820 | +70 | +4% | 54,700 |
| 2024/04/09 | 1,814 | 1,878 | 1,744 | 1,750 | -87 | -4.7% | 57,700 |
| 2024/04/08 | 1,850 | 2,000 | 1,825 | 1,837 | +64 | +3.6% | 106,400 |
| 2024/04/05 | 1,670 | 1,814 | 1,640 | 1,773 | +92 | +5.5% | 120,700 |
| 2024/04/04 | 1,820 | 1,864 | 1,681 | 1,681 | -138 | -7.6% | 110,200 |
| 2024/04/03 | 1,930 | 1,954 | 1,819 | 1,819 | -142 | -7.2% | 91,400 |
| 2024/04/02 | 2,161 | 2,259 | 1,941 | 1,961 | -173 | -8.1% | 247,400 |
| 2024/04/01 | 2,023 | 2,330 | 2,023 | 2,134 | +151 | +7.6% | 436,300 |
| 2024/03/29 | 1,851 | 2,200 | 1,835 | 1,983 | +160 | +8.8% | 356,800 |
| 2024/03/28 | 1,891 | 1,900 | 1,809 | 1,823 | -87 | -4.6% | 71,500 |
| 2024/03/27 | 2,000 | 2,000 | 1,831 | 1,910 | -105 | -5.2% | 294,600 |
| 2024/03/26 | 1,701 | 2,015 | 1,661 | 2,015 | +400 | +24.8% | 572,200 |
| 2024/03/25 | 1,671 | 1,717 | 1,590 | 1,615 | -45 | -2.7% | 71,000 |
| 2024/03/22 | 1,534 | 1,660 | 1,470 | 1,660 | +117 | +7.6% | 160,800 |
| 2024/03/21 | 1,700 | 1,720 | 1,540 | 1,543 | -78 | -4.8% | 147,900 |
| 2024/03/19 | 1,645 | 1,756 | 1,615 | 1,621 | -9 | -0.6% | 75,500 |
| 2024/03/18 | 1,621 | 1,710 | 1,598 | 1,630 | -42 | -2.5% | 63,700 |
| 2024/03/15 | 1,764 | 1,770 | 1,567 | 1,672 | -118 | -6.6% | 188,700 |
| 2024/03/14 | 1,818 | 1,858 | 1,756 | 1,790 | -68 | -3.7% | 68,600 |
| 2024/03/13 | 1,901 | 1,977 | 1,809 | 1,858 | -67 | -3.5% | 71,600 |
| 2024/03/12 | 1,701 | 1,980 | 1,686 | 1,925 | +217 | +12.7% | 207,300 |
| 2024/03/11 | 2,000 | 2,005 | 1,651 | 1,708 | -397 | -18.9% | 311,800 |
| 2024/03/08 | 2,240 | 2,280 | 2,082 | 2,105 | -85 | -3.9% | 89,900 |
| 2024/03/07 | 2,422 | 2,448 | 2,136 | 2,190 | -82 | -3.6% | 212,200 |
| 2024/03/06 | 2,060 | 2,326 | 2,019 | 2,272 | +212 | +10.3% | 219,800 |
| 2024/03/05 | 2,132 | 2,192 | 2,001 | 2,060 | -12 | -0.6% | 192,500 |
| 2024/03/04 | 2,093 | 2,155 | 2,020 | 2,072 | -21 | -1% | 95,300 |
151～
200
件表示中 / 215件
類似銘柄と比較する
現在ご覧いただいている「ＶＩＳ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| ＶＩＳ | 69,500円 | -47.5% | - | 0.00% | - | 1.91倍 |
|
ｍＲＮＡ標的低分子創薬技術を製薬会社に提供。共同創薬研究などによる契約金収入が柱 |
| クリングル | 81,000円 | +240.0% | - | 0.00% | - | 2.64倍 |
|
細胞の増殖、保護、修復などの機能があるＨＧＦタンパク質を用いて、難治性疾患治療薬を開発 |
| カルナバイオ | 27,900円 | -61.2% | - | 0.00% | - | 1.66倍 |
|
キナーゼタンパク質の販売や受託試験など創薬初期の支援事業が柱。キナーゼ阻害剤で創薬も |
| キッズバイオ | 10,400円 | - | - | 0.00% | - | 5.47倍 |
|
北大発創薬ベンチャー。バイオ後続品を主力に、乳歯歯髄幹細胞（ＳＨＥＤ）用いた再生医療に力 |
| 免疫生物 | 45,200円 | +13.4% | -4.0% | 0.00% | 36.60倍 | 3.15倍 |
|
研究用試薬の製販・受託。遺伝子組み換えカイコの基礎研究は休止し、化粧品等応用開発に移行 |
市場注目の銘柄
チャート関連のコラム
